<DOC>
	<DOCNO>NCT01169909</DOCNO>
	<brief_summary>Ranibizumab , effective antineovascular drug , study safety efficacy pterygium , neovascular disorder ocular surface .</brief_summary>
	<brief_title>Efficacy Safety Sub-tenon Ranibizumab Recurrent Pterygia</brief_title>
	<detailed_description>Ptergyia chronic fibrovascular lesion ocular surface . This study design look signal efficacy lesion phase active vascular growth . This phase often catch newly recur pterygia post-operatively . Patients identify actively grow lesion , offer local injection directly beneath lesion . They examine adverse side effect regression lesion .</detailed_description>
	<mesh_term>Pterygium</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Patients actively grow pterygium , either surgical recurrence , nonsurgical primary lesion . Pregnancy History CVA Monocular patient Minors</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Pterygium</keyword>
</DOC>